Healthcare shares split as profits meet rising trial costs

• Biome Australia (ASX:BIO) led the major moves after revenue rose 30% and profit reached $3.6 million.
• Nanosonics (ASX:NAN) fell 24.79% despite trophon growth, a planned CORIS launch and a $40 million buyback.
• Epiminder (ASX:EPI) and Saluda Medical (ASX:SLD) dropped more than 23% as investors weighed large losses and ongoing spending.
• Diagnostics, medical devices and imaging companies reported wider sales reach, new approvals and stronger commercial plans.